New data supporting a fixed-ratio combination of insulin glargine and lixisenatide was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Munich, Germany.
There are currently 3.5 million people in the UK diagnosed with diabetes, a figure predicted to rise to an estimated five million people by 2025. Over two thirds of adults treated with insulin do not reach the NICE target for blood glucose control (HbA1c ≤ 7.5%), increasing their risk of potentially avoidable complications such as amputation, blindness and renal disease.
Dr Mike Baxter, medical therapy expert at Sanofi UK, said: “Blood glucose management in the UK is amongst the worst in Europe with, on average, people with type 2 diabetes having the highest blood glucose levels compared to nine other developed countries. This latest study reflects Sanofi’s ongoing commitment to innovative approaches in developing medicines that are intended to help patients manage their condition and reduce the risk of avoidable complications.”
New results from the LixiLan-L study, a trial investigating a titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide (iGlarLixi) in adults with type 2 diabetes, showed in patients with type 2 diabetes uncontrolled with basal insulin, the fixedratio combination demonstrated greater post meal glycaemic control compared with insulin glargine alone, with consistently more patients reaching postprandial plasma glucose (PPG) targets after all meals throughout the day.
The fixed dose combination of insulin glargine and lixisenatide is currently undergoing licensing review by the European Medicines Agency (EMA).